U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07181239) titled 'Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients' on Sept. 12.
Brief Summary: The purpose of this study is to compare the efficacy between CM336 and investigator's choice Standard of Care in relapsed or refractory multiple myeloma (RRMM) patients.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma (MM)
Intervention:
DRUG: CM336 Injection
Specified dose on specified days
DRUG: Standard Of Care( SOC)
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Keymed Biosciences Co.Ltd
Published by HT Digital Content Services with permission from Heal...